Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

CCR 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells.

Allard WJ, Terstappen LW.

Clin Cancer Res. 2015 Jul 1;21(13):2883-5. doi: 10.1158/1078-0432.CCR-14-2559.

2.

Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.

Moore RG, Hawkins DM, Miller MC, Landrum LM, Gajewski W, Ball JJ, Allard WJ, Skates SJ.

Gynecol Oncol. 2014 Dec;135(3):547-51. doi: 10.1016/j.ygyno.2014.10.017. Epub 2014 Oct 23.

PMID:
25449569
3.

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ.

Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6. doi: 10.1016/j.ajog.2010.03.043. Epub 2010 May 14.

4.

Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.

Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J.

Technol Cancer Res Treat. 2009 Oct;8(5):323-32.

PMID:
19754208
5.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ.

Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.

6.

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K.

Gynecol Oncol. 2008 Aug;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002. Epub 2008 May 21.

7.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr.

Gynecol Oncol. 2008 Feb;108(2):402-8. Epub 2007 Dec 3.

PMID:
18061248
8.

MESOMARK(®) in vitro diagnostic test for mesothelioma.

Li ZQ, Verch T, Allard WJ.

Expert Opin Med Diagn. 2007 Sep;1(1):137-42. doi: 10.1517/17530059.1.1.137.

PMID:
23489276
9.

MESOMARK: a potential test for malignant pleural mesothelioma.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY.

Clin Chem. 2007 Apr;53(4):666-72. Epub 2007 Feb 8.

10.

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ.

Clin Colorectal Cancer. 2006 Jul;6(2):125-32.

PMID:
16945168
11.

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24.

12.

Circulating tumor cells predict survival in patients with metastatic prostate cancer.

Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW.

Urology. 2005 Apr;65(4):713-8.

PMID:
15833514
13.

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW.

J Clin Oncol. 2005 Mar 1;23(7):1420-30. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808.

PMID:
15735118
14.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW.

Clin Cancer Res. 2004 Oct 15;10(20):6897-904.

15.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF.

N Engl J Med. 2004 Aug 19;351(8):781-91.

16.

Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.

Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Lüftner D, Yeung KK, Chan DW, Schwartz MK, Allard WJ.

Anticancer Res. 2001 Mar-Apr;21(2B):1465-70.

PMID:
11396233
17.
18.

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.

Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ.

J Urol. 2000 May;163(5):1476-80.

PMID:
10751861
19.

Analysis of monoclonal antibodies to prostate-specific antigen: reactivity with native and recombinant prostate-specific antigen.

Zhou Z, Barnett TR, Very DL Jr, Ng PC, Pellegrino CM, Davis G, Belenky A, Allard WJ, Yeung KK.

Tumour Biol. 1999;20 Suppl 1:86-93.

PMID:
10628414
20.

Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen.

Stenman UH, Paus E, Allard WJ, Andersson I, Andrès C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Børmer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Hilgers J, et al.

Tumour Biol. 1999;20 Suppl 1:1-12.

PMID:
10628402
21.

Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay.

Allard WJ, Cheli CD, Morris DL, Goldblatt J, Pierre Y, Kish L, Chen Y, Dai J, Vessella RL, Chan DW, Schwartz MK, Zhou Z, Yeung KK.

Int J Biol Markers. 1999 Apr-Jun;14(2):73-83.

PMID:
10399626
22.

Measurement of four tumor marker antigens in the sera of pregnant women.

Cheli CD, Morris DL, Neaman IE, Dai J, Allard WJ, Yeung KK.

J Clin Lab Anal. 1999;13(1):35-9.

23.

Measurement of complexed PSA improves specificity for early detection of prostate cancer.

Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, Allard WJ.

Urology. 1998 Sep;52(3):372-8.

PMID:
9730446
24.

Variation in the quantitation of prostate-specific antigen in reference material: differences in commercial immunoassays.

Cheli CD, Marcus M, Levine J, Zhou Z, Anderson PH, Bankson DD, Bock J, Bodin S, Eisen C, Senior M, Schwartz MK, Yeung KK, Allard WJ.

Clin Chem. 1998 Jul;44(7):1551-3. No abstract available.

25.

Novel immunoassay for the measurement of complexed prostate-specific antigen in serum.

Allard WJ, Zhou Z, Yeung KK.

Clin Chem. 1998 Jun;44(6 Pt 1):1216-23.

26.

Multicenter evaluation of the Bayer Immuno I CA 15-3 assay.

Cheli CD, Morris DL, Kish L, Goldblatt J, Neaman I, Allard WJ, Yeung KK, Wu AH, Moore R, Chan DW, Fritsche HA, Schwartz MK, Very DL Jr.

Clin Chem. 1998 Apr;44(4):765-72.

27.

Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

Morris DL, Dillon PW, Very DL, Ng P, Kish L, Goldblatt JL, Bruzek DJ, Chan DW, Ahmed MS, Witek D, Fritsche HA, Smith C, Schwartz D, Schwartz MK, Noteboom JL, Vessella RL, Yeung KK, Allard WJ.

J Clin Lab Anal. 1998;12(1):65-74.

28.

Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.

Dai J, Allard WJ, Davis G, Yeung KK.

Tumour Biol. 1998;19 Suppl 1:100-10.

PMID:
9422094
29.
30.

Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.

Allard WJ, Neaman IE, Elting JJ, Barnett TR, Yoshimura H, Fritsche HA, Yeung KK.

Cancer Res. 1994 Mar 1;54(5):1227-34.

31.

Antigen binding properties of highly purified bispecific antibodies.

Allard WJ, Moran CA, Nagel E, Collins G, Largen MT.

Mol Immunol. 1992 Oct;29(10):1219-27.

PMID:
1528192
32.

The function but not the expression of rat liver inhibitory guanine nucleotide binding protein is altered in streptozotocin-induced diabetes.

Allard WJ, Vicario PP, Saperstein R, Slater EE, Strout HV.

Endocrinology. 1991 Jul;129(1):169-75.

PMID:
1905225
33.

Purification of ras GTPase activating protein from bovine brain.

Gibbs JB, Schaber MD, Allard WJ, Sigal IS, Scolnick EM.

Proc Natl Acad Sci U S A. 1988 Jul;85(14):5026-30.

34.

Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor.

Allard WJ, Sigal IS, Dixon RA.

Nucleic Acids Res. 1987 Dec 23;15(24):10604. No abstract available.

35.

The glucose transporter in human fibroblasts is phosphorylated in response to phorbol ester but not in response to growth factors.

Allard WJ, Gibbs EM, Witters LA, Lienhard GE.

Biochim Biophys Acta. 1987 Jul 29;929(3):288-95.

PMID:
3300786
36.
37.

Sequence and structure of a human glucose transporter.

Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, Allard WJ, Lienhard GE, Lodish HF.

Science. 1985 Sep 6;229(4717):941-5.

PMID:
3839598
39.

Alloreactive T-cell clones. Ly phenotypes predict both function and specificity for major histocompatibility complex products.

Rao A, Allard WJ, Hogan PG, Rosenson RS, Cantor H.

Immunogenetics. 1983;17(2):147-65.

PMID:
6600709
40.

Supplemental Content

Loading ...
Support Center